Achaogen Inc (NASDAQ:AKAO)’s share price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $3.82 and last traded at $4.06, with a volume of 49412 shares changing hands. The stock had previously closed at $4.12.

AKAO has been the topic of a number of recent analyst reports. BidaskClub raised shares of Achaogen from a “hold” rating to a “buy” rating in a research report on Monday, June 18th. Wedbush reduced their price target on shares of Achaogen from $21.00 to $20.00 and set an “outperform” rating on the stock in a research report on Wednesday, June 27th. lifted their price target on shares of Achaogen to $2.54 and gave the stock a “sell” rating in a research report on Tuesday, July 3rd. ValuEngine lowered shares of Achaogen from a “hold” rating to a “sell” rating in a report on Tuesday, July 10th. Finally, Zacks Investment Research lowered shares of Achaogen from a “hold” rating to a “sell” rating in a report on Wednesday, July 25th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $18.95.

The firm has a market capitalization of $198.92 million, a P/E ratio of -1.23 and a beta of 0.67. The company has a current ratio of 3.79, a quick ratio of 3.79 and a debt-to-equity ratio of 0.42.

Achaogen (NASDAQ:AKAO) last announced its earnings results on Monday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.19). The company had revenue of $2.56 million for the quarter, compared to the consensus estimate of $1.49 million. Achaogen had a negative return on equity of 146.50% and a negative net margin of 2,286.21%. equities analysts predict that Achaogen Inc will post -3.78 earnings per share for the current year.

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of Achaogen by 2.1% during the 1st quarter. BlackRock Inc. now owns 2,898,459 shares of the biopharmaceutical company’s stock worth $37,536,000 after acquiring an additional 60,613 shares during the period. Prosight Management LP increased its position in Achaogen by 15.8% during the 1st quarter. Prosight Management LP now owns 661,054 shares of the biopharmaceutical company’s stock worth $8,561,000 after purchasing an additional 90,134 shares in the last quarter. UBS Group AG increased its position in Achaogen by 681.5% during the 1st quarter. UBS Group AG now owns 297,632 shares of the biopharmaceutical company’s stock worth $3,854,000 after purchasing an additional 259,546 shares in the last quarter. Candriam Luxembourg S.C.A. increased its position in Achaogen by 29.0% during the 1st quarter. Candriam Luxembourg S.C.A. now owns 222,555 shares of the biopharmaceutical company’s stock worth $2,882,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Gabelli Funds LLC increased its position in Achaogen by 18.6% during the 2nd quarter. Gabelli Funds LLC now owns 206,400 shares of the biopharmaceutical company’s stock worth $1,787,000 after purchasing an additional 32,400 shares in the last quarter. 60.61% of the stock is owned by institutional investors.

About Achaogen (NASDAQ:AKAO)

Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.

Read More: Diversification

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.